Post by
DJDawg on Jun 09, 2023 5:04pm
Questions to be asked at AGM (from those who cannot attend)
I'm starting a brainstorming list of question and adjust the wording based on suggestions from the group. I realize the big question is what is the plan to obtain money to keep lights on. But beyond that...my other questions are?
1. Most news releases and updates from the company reference ongoing work on the IV Rutherrin but use the same phrasing over and over again. "Once Rutherrin®’s Maximum Tolerated Dose (“MTD”) and hence Human Equivalent Dose (“HED”) limits have been determined
through non-Good Laboratory Practices (“GLP”) and GLP toxicology studies, Theralase®, subject to the required regulatory approvals, plans to inject Rutherrin® systemically into patients via a Phase Ib clinical study, to allow localization to various cancer cells, including Glio Blastoma Multiforme (“GBM”) and Non-Small Cell Lung Cancer (“NSCLC”) and then activate Rutherrin® with radiation with the
intent of safely and effectively destroying the cancer of interest." The repetive wording does not suggest any progress.
Question: What progress has been made towards an IND application? Is one expected this year, next year or beyond that?
2. How concrete are the recently referenced plans to expand the number of sites recruiting for the NMIBC study? For example, have the sites been determined? Have research applications been made? Have local PI's been identified.
Just two to start but others who cannot attend could add any questions.
Comment by
Dreimer200 on Jun 09, 2023 8:10pm
Excellent questions – well expressed. What happened to 1 and 2?
Comment by
N0taP00p on Jun 09, 2023 9:31pm
DjDawg asked 1 and 2. Well, technically 3.